



NEWS RELEASE

# Castle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner

6/14/2024

Maetzold selected as a winner of Ernst & Young's prestigious annual awards among 48 visionary finalists in the Gulf South region, encompassing Central and South Texas, Louisiana and Mississippi

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer, Derek Maetzold, has been named by Ernst & Young LLP (EY) as an Entrepreneur Of The Year® 2024 Gulf South Award winner. Now in its 38th year, Entrepreneur Of The Year is the preeminent competitive awards program that celebrates entrepreneurs and leaders of high-growth companies who disrupt markets, revolutionize sectors and have a transformational impact on lives.

"I am deeply honored and humbled to have been selected as the recipient of this esteemed award among the many other game-changing entrepreneurs who are also striving to make a difference," said Maetzold. "At Castle, success is not just about the bottom line. It is about making a meaningful impact in this world by keeping people first — the patients and clinicians we serve, our employees and our investors — and by relentlessly pursuing excellence and innovation in all that we do."

Maetzold was selected by an independent judging panel made up of previous award winners, leading CEOs and other business leaders. Candidates were evaluated based on their ability to create long-term value through entrepreneurial spirit, commitment to their purpose and the demonstration of growth and substantial impact, among other core contributions and attributes.



Maetzold founded Castle Biosciences in 2008 in an effort to improve care for patients with rare cancers. This foundational premise — that all patients deserve access to innovative tests that harness their unique biology to help clinicians make more informed choices for their care — continues to infuse the Company's mission, vision, values and culture. Since its inception, the Company has grown from three initial employees to more than 690 nationwide, with revenue of approximately \$220 million in 2023.

Entrepreneur Of The Year recognizes many different types of business leaders for their ingenuity, courage and entrepreneurial spirit. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to fortify it for the future.

As a Gulf South award winner, Maetzold is now eligible for consideration for the Entrepreneur Of The Year 2024 National Awards. The National Award winners, including the Entrepreneur Of The Year National Overall Award winner, will be announced in November at the **Strategic Growth Forum®**, one of the nation's most prestigious gatherings of high-growth, market-leading companies. The Entrepreneur Of The Year National Overall Award winner will then move on to compete for the World Entrepreneur Of The Year Award in June 2025.

The comprehensive list of Entrepreneur Of The Year 2024 Gulf South Award winners can be viewed [here](#).

## Sponsors

Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting sponsors PNC Bank, Cresa, Marsh USA, SAP and the Ewing Marion Kauffman Foundation. In the Gulf South, sponsors also include ADP, DLA Piper, Marsh McLennan Agency, vcfo, Big Picture Inc., and Pierpont Communications.

## About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit

[www.CastleBiosciences.com](http://www.CastleBiosciences.com) and connect with us on [LinkedIn](#), [Facebook](#), [X](#) and [Instagram](#).

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

## About Entrepreneur Of The Year®

Founded in 1986, Entrepreneur Of The Year® has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the U.S., and it has since expanded to nearly 80 countries and territories globally.

The U.S. program consists of 17 regional programs whose panels of independent judges select the regional award winners every June. Those winners compete for national recognition at the Strategic Growth Forum® in November where National finalists and award winners are announced. The overall National winner represents the U.S. at the World Entrepreneur Of The Year® competition. Visit [ey.com/us/eoy](https://ey.com/us/eoy).

## About EY

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via [ey.com/privacy](https://ey.com/privacy). EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit [ey.com](https://ey.com).

## Investor Contact:

Camilla Zuckero

[czuckero@castlebiosciences.com](mailto:czuckero@castlebiosciences.com)

Media Contact:

Allison Marshall

**[amarshall@castlebiosciences.com](mailto:amarshall@castlebiosciences.com)**

Source: Castle Biosciences Inc.